Abstract Details

Title Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Chronic Migraine: Results of a 1-Year Study

Topic Headache

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-015

Objective To evaluate the long-term effect of fremanezumab on response rates, acute headache medication use, and disability in adults with chronic migraine (CM).

Background Migraine preventive treatment is intended to reduce the frequency, severity, and disability of migraine attacks. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine.

Design/Methods In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM received either subcutaneous fremanezumab monthly (225 mg every month with a starting dose of 675 mg) or quarterly (675 mg every 3 months). The percentage of patients achieving ≥50% reduction in monthly average number of headache days of at least moderate severity or migraine days, the mean change from baseline in the monthly number of days of use of any acute headache medications, and the mean change from baseline in Headache Impact Test (HIT-6) score (assessing disability) were assessed.

Results This study enrolled 1110 patients with CM. The proportion achieving ≥50% reduction in monthly average number of headache days of at least moderate severity at Month 12 was 54% with quarterly dosing and 59% with monthly dosing. The proportion achieving ≥50% reduction in monthly average number of migraine days at Month 12 was 53% with quarterly dosing and 57% with monthly dosing. The mean change in monthly number of days of use of any acute headache medications from baseline to Month 12 was –6.0 days in the quarterly group and –6.2 days in the monthly treatment group. HIT-6 scores decreased by 8.4 and 7.7 at the end of treatment for the monthly and quarterly groups, respectively, meeting the minimally important difference.

Conclusions

Efficacy, decreased acute medication use, and improvements in disability were maintained through 12 months of treatment with fremanezumab in patients with CM.

Authors/Disclosures
Peter J. McAllister, MD, FAAN (New England Inst for Neurology and Headache) PRESENTER	Dr. McAllister has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for pfizer. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lilly. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for abbvie. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lundbeck.
Paul P. Yeung, MD, PhD	No disclosure on file
	No disclosure on file
Sanjay Gandhi, MD (Teva Pharmaceuticals)	Dr. Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals.
	No disclosure on file

��ɫ��

��ɫ��